Maurizio Bonfichi
Pavia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Journal: HemaSphere
Published: May 19, 2022
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Journal: Annals of hematology
Published: February 04, 2021
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.
Journal: Annals of hematology
Published: November 21, 2020
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
Journal: Haematologica
Published: February 13, 2020
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Journal: Blood advances
Published: September 16, 2019
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Journal: Annals of hematology
Published: April 08, 2019
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Journal: Hematological oncology
Published: April 30, 2018
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Journal: Haematologica
Published: April 26, 2017
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.
Journal: Oncotarget
Published: April 04, 2017
Last Updated: 09/26/2026